<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="zh-Hans-CN">
	<id>https://www.yiliao.com/index.php?action=history&amp;feed=atom&amp;title=%E9%87%91%E8%AF%BA%E8%8A%AC</id>
	<title>金诺芬 - 版本历史</title>
	<link rel="self" type="application/atom+xml" href="https://www.yiliao.com/index.php?action=history&amp;feed=atom&amp;title=%E9%87%91%E8%AF%BA%E8%8A%AC"/>
	<link rel="alternate" type="text/html" href="https://www.yiliao.com/index.php?title=%E9%87%91%E8%AF%BA%E8%8A%AC&amp;action=history"/>
	<updated>2026-04-21T17:23:21Z</updated>
	<subtitle>本wiki的该页面的版本历史</subtitle>
	<generator>MediaWiki 1.35.1</generator>
	<entry>
		<id>https://www.yiliao.com/index.php?title=%E9%87%91%E8%AF%BA%E8%8A%AC&amp;diff=128575&amp;oldid=prev</id>
		<title>112.247.109.102：以“通用名称：金诺芬  英文名称：Auranofin  中文别名：金兰诺芬、金葡芬、立达金  英文别名：Aurothioglycolanilide  本品...”为内容创建页面</title>
		<link rel="alternate" type="text/html" href="https://www.yiliao.com/index.php?title=%E9%87%91%E8%AF%BA%E8%8A%AC&amp;diff=128575&amp;oldid=prev"/>
		<updated>2014-01-27T04:59:06Z</updated>

		<summary type="html">&lt;p&gt;以“&lt;a href=&quot;/%E9%80%9A%E7%94%A8%E5%90%8D&quot; class=&quot;mw-redirect&quot; title=&quot;通用名&quot;&gt;通用名&lt;/a&gt;称：&lt;a href=&quot;/%E9%87%91%E8%AF%BA%E8%8A%AC&quot; title=&quot;金诺芬&quot;&gt;金诺芬&lt;/a&gt;  英文名称：Auranofin  中文别名：&lt;a href=&quot;/%E9%87%91%E5%85%B0&quot; title=&quot;金兰&quot;&gt;金兰&lt;/a&gt;诺芬、金葡芬、&lt;a href=&quot;/%E7%AB%8B%E8%BE%BE%E9%87%91&quot; title=&quot;立达金&quot;&gt;立达金&lt;/a&gt;  英文别名：Aurothioglycolanilide  本品...”为内容创建页面&lt;/p&gt;
&lt;p&gt;&lt;b&gt;新页面&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[通用名]]称：[[金诺芬]]&lt;br /&gt;
&lt;br /&gt;
英文名称：Auranofin&lt;br /&gt;
&lt;br /&gt;
中文别名：[[金兰]]诺芬、金葡芬、[[立达金]]&lt;br /&gt;
&lt;br /&gt;
英文别名：Aurothioglycolanilide&lt;br /&gt;
&lt;br /&gt;
本品性质稳定，含金约29％，微溶于水，易溶于类脂体中。{{百科小图片|bk26e.jpg|}}　　&lt;br /&gt;
==药理及应用==&lt;br /&gt;
有抗炎作用，起效慢。口服后所含金的25％被吸收，其中60％与[[血浆蛋白结合]]，40％与[[细胞]]结合。本品主要由粪便排出。长期服用本品，金[[血浆]]浓度12周达高峰，并可保持稳定状态。主用于活动性[[类风湿性关节炎]]，亦用于对[[非甾体抗炎药]]效果不显或无法耐受患者，可延缓类风湿性关节炎病变发展，改善[[症状]]，耐受好。　　&lt;br /&gt;
==用法==&lt;br /&gt;
口服：成人量1日mg，于早饭后服，或早、晚饭后各服3mg。初始剂量1日mg，2周后增至 1日／6mg。如服6个月后疗效不显，可增至一日mg，分3次服。若此量连服3个月效果仍不显，应停药。　　&lt;br /&gt;
==注意==&lt;br /&gt;
(1)常见[[副作用]]有[[腹泻]]，[[腹痛]]、[[恶心]]、胃肠不适。尚可见[[皮疹]]、[[瘙痒]]。[[口腔炎]]、[[结膜炎]]少见。国外报道有[[白细胞]]、[[血小板减少]]、[[紫癜]]、单纯红细胞发育不全、暂时性[[蛋白尿]]、[[血尿]]等及[[肝功能]]短时异常。&lt;br /&gt;
&lt;br /&gt;
(2)对金过敏、[[坏死性小肠结肠炎]]、[[肺纤维化]]、[[剥脱性皮炎]]、[[骨髓]]再生障碍、进行性[[肾炎]]、严重[[肝病]]患者以及孕妇、哺乳妇女慎用。&lt;br /&gt;
&lt;br /&gt;
(3)服用本品前应检查血、[[尿常规]]，[[血小板计数]]，肝、[[肾功能]]。&lt;br /&gt;
&lt;br /&gt;
[制剂] 片剂：每片3mg。[[胶囊剂]]：每[[胶囊]]3mg。薄膜片：每片3mg(含金0．87mg)。　　&lt;br /&gt;
==药理作用==&lt;br /&gt;
Classification: Antiarthritic,oral gold compound&lt;br /&gt;
&lt;br /&gt;
Action/Kinetics: Auranofin is agold-containing (29%) compound for PO administration. It has fewer side effects thaninjectable gold products. Although the mechanism is not known, auranofin will improvesymptoms of rheumatoid arthritis; it is most effective in the early stages of activesynovitis and may act by inhibiting sulfhydryl systems. Other possible mechanisms includeinhibition of phagocytic activity of macrophages and polymorphonuclear leukocytes,alteration of biosynthesis of collagen, and alteration of the immune response. Gold willnot reverse damage to joints caused by disease. Approximately 25% of an oral dose isabsorbed. Plasma t1/2 of auranofin gold: 26 days. Onset: 3-4 months(up to 6 months in certain clients). Approximately 3 months are required for steady-stateblood levels to be achieved. The drug is metabolized and excreted in both the urine andfeces.　　&lt;br /&gt;
==[[适应症]]==&lt;br /&gt;
Adults and children withrheumatoid arthritis that have not responded to other drugs. Up to 6 months may berequired for beneficial effects to occur. Auranofin should be part of a total treatmentregimen for rheumatoid arthritis, including nondrug treatments.　　&lt;br /&gt;
==用法用量==&lt;br /&gt;
Capsules Rheumatoid arthritis. Adults, initial: Either 6 mg/day or 3 mg b.i.d. If response is unsatisfactory after6 months, increase to 3 mg t.i.d. If response is still inadequate after 3 additionalmonths, discontinue the drug. Dosages greater than 9 mg/day are not recommended. Children, initial: 0.1 mg/kg/day; maintenance: 0.15 mg/kg/day, not to exceed0.2 mg/kg/day. Transfer from injectable gold. Discontinue injectable gold and begin auranofin at a dose of 6 mg/day.　　&lt;br /&gt;
==注意事项==&lt;br /&gt;
Pregnancy Category: C&lt;br /&gt;
&lt;br /&gt;
Contraindications: History ofgold-induced disorders including necrotizing enterocolitis, pulmonary fibrosis,exfoliative dermatitis, bone marrow aplasia, or other hematologic severe disorders. Useduring lactation.&lt;br /&gt;
&lt;br /&gt;
Special Concerns: Use withextreme caution in renal or hepatic disease, skin rashes, marked hypertension, compromisedcerebral or CV circulation, or history of bone marrow depression (e.g., agranulocytopenia,anemia). Gold dermatitis may be aggravated by exposure to sunlight. Although used inchildren, a recommended dosage has not been established. Tolerance to gold is oftendecreased in geriatric clients.　　&lt;br /&gt;
==[[不良反应]]==&lt;br /&gt;
GI: N&amp;amp;amp;V, diarrhea (common), abdominal pain, metallic taste, stomatitis, glossitis,gingivitis, anorexia, constipation, flatulence, dyspepsia, dysgeusia, melena. Rarely,dysphagia, GI bleeding, ulcerative enterocolitis. Dermatologic: Skin rashes, pruritus, alopecia, urticaria, angioedema, actinic rash. Hematologic: Leukopenia, anemia, thrombocytopenia (with or without purpura), neutropenia,agranulocytosis, eosinophilia, pancytopenia, hypoplastic anemia, aplasticanemia pure red cell aplasia. Renal: Proteinuria, hematuria. Hepatic: Jaundice (with or without cholestasis, hepatitis with jaundice, toxichepatitis intrahepatic cholestasis. Other: Conjunctivitis,cholestatic jaundice, fever, interstitial pneumonia and fibrosis, peripheral neuropathy.　　&lt;br /&gt;
==[[药物过量]]==&lt;br /&gt;
Symptoms: Rapid appearance of hematuria, proteinuria, thrombocytopenia, granulocytopenia. Also,N&amp;amp;amp;V, diarrhea, fever, urticaria, papulovesicular lesions, urticaria, exfoliativedermatitis, pruritus. Treatment: Discontinue promptly and give dimercaprol.Supportive therapy should be provided for renal and hematologic symptoms. Treat moderatelysevere skin and mucous membrane symptoms with topical corticosteroids, oralantihistamines, and anesthetic lotions. Treat severe stomatitis or dermatitis withprednisone, 10-40 mg daily. Treat serious renal, hematologic, pulmonary, and enterocoliticcomplications with prednisone, 40-100 mg daily in divided doses. The duration of treatmentvaries, depending on the severity of symptoms and the response to steroids. In acuteoverdosage, induce emesis or perform gastric lavage immediately.&lt;br /&gt;
&lt;br /&gt;
[[分类:药理学]][[分类:中枢神经系统用药]][[分类:解热镇痛抗痛风药]][[分类:抗炎镇痛药]]&lt;/div&gt;</summary>
		<author><name>112.247.109.102</name></author>
	</entry>
</feed>